Detailed explanation of indications for Mirikizumab

Mirikizumab (Mirikizumab), also known as Omvoh, is a new generation of interleukin-23 antagonist, mainly used to treat adults with moderate to severe active ulcerative colitis (UC). The drug, administered via intravenous or subcutaneous injection, specifically targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting the IL-23 signaling pathway. As a natural cytokine, IL-23 plays an important role in normal immune and inflammatory responses, but in patients with ulcerative colitis, its overactivation is considered to be a key factor leading to inflammation and related symptoms.

The mechanism of action of Omvoh is to effectively reduce the intestinal inflammatory response by blocking IL-23, thereby inhibiting the release of cytokines and chemokines related to inflammation. Milizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2023, marking a major progress in its clinical application.

Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulceration of the lining of the large intestine. The pathogenesis of this disease is complex and involves multiple immune and genetic factors. In particular, the activity of IL-23 is closely related to mucosal inflammation. Clinical studies have shown that in the induction and maintenance treatment of patients with ulcerative colitis, there is a significant positive correlation between the plasma concentration of Omvoh and clinical remission rate and response, demonstrating its good efficacy.

By binding toIL-23 and its receptor, militizumab can effectively inhibit the interaction between these factors and regulate the production of relevant cytokines that drive the pathogenesis of ulcerative colitis. This new treatment modality brings new hope to patients with moderate to severe ulcerative colitis.

Reference materials:https://www.drugs.com/omvoh.html